Alzyn

Alzyn is a biotechnology company headquartered in Tallahassee, Florida, focused on developing therapeutic interventions for Alzheimer's disease and age-related cognitive decline. The company's lead product candidate is a proprietary formulation consisting of acetyl-L-carnitine, vitamin B12, and folic acid, which aims to inhibit the formation of amyloid-beta plaques and tau tangles. Based on research licensed from Florida State University, Alzyn targets the early stages of neurodegeneration to slow the progression of memory loss. The company positions its lead candidate as a medical food or therapeutic supplement that has shown neuroprotective promise in clinical pilot studies. Alzyn continues to pursue clinical validation and commercialization strategies for its nutritional therapeutic approach.